Asset profile
GM-XANTHO
Botanical
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Atopic Dermatitis · Phase 1/2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
113 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 113 same-indication; 79 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| GM-XANTHO: this drug | Phase 2 | Botanical | Macrophage inflammatory response | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| Brodalumab (Siliq) | Approved | Monoclonal antibody | IL-17 receptor A | ||
| Calcipotriene / Betamethasone Dipropionate Cream (Wynzora) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Calcipotriene / Betamethasone Dipropionate Foam (Enstilar) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Desoximetasone (Topicort Spray) | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha |
…and 98 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.